Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 27, 2025
Product Development
Editas: The high-risk, high-reward gene editing pioneer
Editas set out to bring a new technology — CRISPR-Cas9 — to indications not served by existing therapeutic modalities
BioCentury | May 13, 2022
Data Byte
Distillery spotlight on Italian innovation
Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders
BioCentury | Feb 12, 2022
Product Development
Challenging rare eye indication sinks a second modality
ProQR’s sepofarsen, an antisense oligonucleotides, stumbles in late-stage trial for LCA10
BioCentury | Sep 29, 2021
Product Development
Without biomarker data, Editas results fail to impress
Despite strong safety signals and signs of efficacy
BioCentury | Apr 6, 2021
Product Development
Leber congenital amaurosis pipeline: Data Byte
The Leber congenital amaurosis pipeline includes at least 10 products in development targeting the most common genetic causes of the disease, including seven gene therapies, a gene editing candidate,
BioCentury | Apr 5, 2021
Product Development
ProQR readies second antisense program for pivotal testing
ProQR is readying to advance a second RNA-based antisense oligonucleotide therapy for inherited retinal diseases into pivotal testing on the back of positive early data for QR-421a late last
BioCentury | Sep 30, 2019
Company News
Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan
BioCentury | Jul 25, 2019
Clinical News
July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea
BioCentury | Jul 24, 2019
Company News
July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more
BioCentury | May 28, 2019
Distillery Therapeutics
Split intein-based gene therapies for two types of congenital blindness
Items per page:
1 - 10 of 34